1831P - Obesity and weight variations before treatment, seem to influence weight loss that happens during first-line metastatic lung adenocarcinoma

Background

Weight loss (WL) is crucial to monitor in metastatic lung adenocarcinoma, given that studies strongly support an association between WL and outcome. We aim to study weight variation and its mechanisms according to cancer treatment, cancer catabolism, and metabolic factors such as obesity and WL before treatment.

Methods

We analyzed patients with metastatic lung adenocarcinoma during the first-line treatment. Weight was recorded at four time points: before treatment (Wbe), on day one of treatment (Wd1), at the beginning of maintenance or three months of immune checkpoint inhibitors treatment (W3mo), and at progression (Wpro).

Results

Patients n=198 were retrospectively included; most of them are men (56%); 47% of patients received chemotherapy (CT) associated with immune checkpoint inhibitors (ICIs), 26% CT alone, and 27% ICI alone. On day one of treatment, 11% were considered malnourished according to BMI (Body Mass Index) (BMI£18.5), and 32% were overweight or obese (BMI³25). WL ≥ 5% before treatment has been observed in 37% of patients. Mean (SD) weight variation was respectively for CT alone, CT+ICI, and ICI alone: -1.1% (4.6); -0.2% (7.1); 0.4% (7.7) (p=0.52).

Conclusions

No differences were observed in weight variation at different assessment points and between cancer treatment types. The results suggest that the control of the intense catabolism by cancer treatment maintains patients’ weight irrespective of digestive disorders. On the contrary, digestive disorders can lead to weight loss when catabolism is less intensive. Weight loss during cancer treatment seems to be influenced by the initial nutritional status since we found that faster weight loss occurred in patients with a higher BMI.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.